Jonathan D Marotti
Overview
Explore the profile of Jonathan D Marotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tau S, Chamberlin M, Yang H, Marotti J, Muskus P, Roberts A, et al.
Cancer Res
. 2025 Jan;
85(6):1145-1161.
PMID: 39777474
Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain...
2.
Chen Y, Salas L, Marotti J, Jenkins N, Cheng C, Miller T, et al.
Int J Cancer
. 2024 Dec;
156(6):1191-1202.
PMID: 39635770
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with substantial disease heterogeneity, limited treatment options, and dismal clinical outcomes. Some TNBCs display homologous recombination deficiency (HRD), a...
3.
Goyal M, Marotti J, Workman A, Tooker G, Ramin S, Kuhn E, et al.
NPJ Breast Cancer
. 2024 Oct;
10(1):93.
PMID: 39426965
Breast cancer is the most common malignancy affecting women worldwide and is notable for its morphologic and biologic diversity, with varying risks of recurrence following treatment. The Oncotype DX Breast...
4.
Tau S, Chamberlin M, Yang H, Marotti J, Roberts A, Carmichael M, et al.
bioRxiv
. 2024 Oct;
PMID: 39386444
Statement Of Significance: Endocrine-tolerant persister cancer cells that survive endocrine therapy can cause recurrent disease. Persister cells exhibit increased energetic dependence upon mitochondria for survival and tumor re-growth potential.
5.
Jennings E, Percarpio R, Tafe L, Demidenko E, Levy J, Gutmann E, et al.
J Am Soc Cytopathol
. 2024 Apr;
13(4):263-271.
PMID: 38677893
Introduction: The onset of the COVID-19 pandemic, with urgent implementation of safety protocols limiting the number of on-site personnel, essentially terminated the use of rapid on-site evaluation (ROSE) for computed...
6.
Workman A, Green D, Hughes E, Shah P, Cloutier J, Marotti J
Int J Surg Pathol
. 2024 Feb;
32(8):1525-1530.
PMID: 38356303
The entity commonly referred to as chondrolipoma is a rare and enigmatic breast lesion with unclear histogenesis and a complete lack of molecular characterization. It is uncertain whether it represents...
7.
8.
Motanagh S, Dwan D, Azizgolshani N, Muller K, diFlorio-Alexander R, Marotti J
Breast Cancer (Auckl)
. 2023 Nov;
17:11782234231215193.
PMID: 38034324
Background: Breast magnetic resonance imaging (MRI) is an important imaging tool for the management of breast cancer patients and for screening women at high risk for breast cancer. Objectives: To...
9.
Martinez Coconubo D, Levy J, Kerr D, Vaickus L, Vidis L, Glass R, et al.
J Am Soc Cytopathol
. 2023 Sep;
12(6):451-460.
PMID: 37775434
Introduction: The suggested atypia of undetermined significance (AUS) rate for thyroid fine-needle aspiration biopsies is 10% or less. Prompted by a high institutional AUS rate, we examined using molecular testing...
10.
Traphagen N, Schwartz G, Tau S, Roberts A, Jiang A, Hosford S, et al.
Clin Cancer Res
. 2023 Jul;
29(18):3717-3728.
PMID: 37439680
Purpose: Clinical evidence indicates that treatment with estrogens elicits anticancer effects in ∼30% of patients with advanced endocrine-resistant estrogen receptor α (ER)-positive breast cancer. Despite the proven efficacy of estrogen...